Extra Strength Pain Reliever Acetaminophen Recalled for cGMP Deviations
Ultra Seal Corporation is recalling Extra Strength Pain Reliever (acetaminophen 500 mg) 2 tablet packets nationwide due to cGMP deviations. The recall affects Lot #AK9602 with expiration date 05/2022.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for cGMP deviations without reported illnesses or injuries. The recall is voluntary and precautionary in nature, addressing manufacturing process defects rather than a confirmed product hazard.
Plain-English summary
Ultra Seal Corporation is recalling Extra Strength (ES) Pain Reliever tablets containing 500 mg acetaminophen in 2 tablet packets. The recall was initiated on January 24, 2022, and covers approximately 297,050 packets distributed nationwide within the United States.
The recall is due to Current Good Manufacturing Practice (cGMP) deviations identified during manufacturing. The affected product is Lot #AK9602 with expiration date 05/2022.
This is a voluntary recall initiated by the firm. The FDA classified this recall as Class II. The recall was terminated on October 16, 2023. Consumers who have purchased this product should discontinue use and consult with a healthcare provider or pharmacist if they have questions.
The recalled product
- Product
- Extra Strength (ES) PAIN RELIEVER (acetaminophen 500 mg) 2 tablet packets, Manufactured by Ultratab Laboratories, Inc.
- Manufacturer
- Ultra Seal Corporation
- Hazard
- cgmp-deviation
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: AK9602
- Exp. Date 05/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27